Hangzhou Diagens Biotechnology Co., Ltd. (HKG:2526)

Market Cap	8.14B
Revenue (ttm)	211.63M +160.6%
Net Income	-140.48M
EPS	-1.69
Shares Out	88.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	402,350
Open	94.60
Previous Close	94.75
Day's Range	90.30 - 99.80
52-Week Range	89.80 - 765.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About HKG:2526

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company’s products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Employees: 174
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2526

Financial Performance

In 2025, HKG:2526's revenue was 164.42 million, an increase of 133.72% compared to the previous year's 70.35 million. Losses were -67.14 million, 54.8% more than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error